U.S. Patent and Trademark Office, It Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number		10595940			
Filing Date		2006-05-19			
First Named Inventor Koba		ayashi et al.			
Art Unit		N/A			
Examiner Name N/A					
Attornou Docket Number		TAK2146.002			

	U.S.PATENTS				Remove						
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>				Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear				
	1										
If you wis	h to a	dd additional U.S. Pate	nt citatio	n inform	ation p	lease click the	Add button.	_	Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	ation	Name of Pat of cited Docu	entee or Applicant iment	Releva		Lines where	
	1										
If you wish	h to a	dd additional U.S. Publ	ished Ap	plication	n citatio	n information p	olease click the Ad	d buttor	. Add		
				FOREIG	GN PA	TENT DOCUM	IENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Countr Code <sup>2</sup>		Kind Code <sup>4</sup>	Publication Date	Name of Patente Applicant of cited Document	e or	where Re	or Relevant	74
	1	63-41133	JP		Y2	1988-10-27	Komatsu Chemica Co., Ltd.	ls,			Ø
	2	09-089165	JP		A	1997-03-31	Sumitomo Wiring S Ltd	Syst			V
	3	2000-108821	JP		A	2000-04-18	Fuji Heavy Ind Ltd				V

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) This land the state of the state of

Application Number		10595940		
iling Date		2006-05-19		
irst Named Inventor Koba		yashi et al.		
Art Unit		N/A		
Examiner Name N/A				
Months of Number	er	TAK2146-002		

	4	2000-156921	JP	A	2000-06-06	Yazaki Corp		V
	5	2002-059794	JP	A	2002-02-26	Suzuki Motor Corp		Z
	6	2003-191279	JP	A	2003-07-08	Canon Inc		V
If you wie	f you wish to add additional Egging Patent Decument citation information please click the Add button Add							

Examine Cite Include name of the author (in CAPITAL LETTERS), itse of the article (when appropriate), itse of the item Initials' No (block, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city androic country where published.

,

If you wish to add additional non-patent literature document citation information please click the Add button Add

# EXAMINER SIGNATURE

Examiner Signature Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kind. Codes of USPTO Patent Documents at swee\_USPTO\_QDV or MFPP 06164. \* Enter office that issued the document, by the No-Netro code (WIPO Standard ST3.) \* For Liquidates operation counters, the ancidation of the year of the region of the Emporter manaprecess the sensal number of the pathod for the Counter of the Contract of the

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10595940		
Filing Date		2006-05-19		
First Named Inventor Koba		yashi et al.		
Art Unit		N/A		
Examiner Name N/A				
Attorney Docket Number		TAK2146-002		

#### CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

	That each item of information contained in the information disclosure statement was first cited in any communication
П	from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
_	information disclosure statement, See 37 CFR 1.97(e)(1).

### OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 175(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 179(vic).

- Fee set forth in 37 CFR 1,17 (p) has been submitted herewith.
- 7 None

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Eric M. Gayan/	Date (YYYY-MM-DD)	2006-08-24
Name/Print	Enc M. Gavan	Registration Number	46.103

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is foll field end by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenar's Office, U.S. Operatment of Commence, P. 0. Bot 1450, Alexandria, V.3231-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. 0. Box 1450, Alexandria, V.2231-1450.

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually intermediate or for extension or about those when the basic high process another examines your submission, which may visually intermediate or for extension or a submission of the basic high process another examines your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pusuant to 5 U.S.C. 552a(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandomed or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.